Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 18

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 18
---
2038 APOC3 2035, 2038 ATXN2 2044 C3 2043 CFB 2044 COVID 2043 Cx43 2029 DM1 2043 DUX4 2041 Factor 12 2036, 2038 FRP-1 2026 HBV 2032, 2036, 2037 HIF1A 2026 HIF2α 2034, 2036, 2040 HRH1 2027 HSD17B13 2039 HSF1 2030, 2032 KRAS 2033 LPA 2036 MARC1 2044 MMP7 2042 Mob-5 2027 MUC5AC 2042 P2X3 2027 PCSK9 2044 PDtype4 2026 PI4Kinase 2028 PNPLA3 2041 RAGE (AGER) 2042 RRM2 2031 SOD1 2043 SYK 2027 TNF-α 2027, 2028 TSLP 2044 XDH 2042 α-ENaC 2028, 2038 β-Catenin 2033 β-ENaC 2031, 2040 *Assuming issuance of any pending patent applications, and excluding any patent term adjustments or patent term extensions. Delivery Technologies: The delivery technology-related patents and patent applications, which include components used in the Company’s TRiMTM platform, have been filed and/or issued in various jurisdictions worldwide including the United States, Argentina, Australia, Brazil, Canada, China, Eurasian Patent Organization, Europe (including validations in France, Germany, Italy, Spain, Switzerland, United Kingdom), GCC (Gulf Cooperation Council), Israel, India, Japan, Lebanon, Mexico, New Zealand, Philippines, Russia, South Africa, South Korea, Singapore, 10

Taiwan, and Uruguay. The Company also controls a patent directed to hydrodynamic nucleic acid delivery that issued in the United States. However, the Company cannot guarantee that issued patents will be enforceable or provide adequate protection for the Company, or that pending patent applications will result in issued patents. These various groups of patents and applications are set forth below: Patent Group Estimated Year(s) of Expiration* Targeting ligands and other RNAi delivery and platform technologies CNS Intrathecal Delivery Platform 2043 Adipose Delivery Platform 2044